Cancer- and chemotherapy-induced anemia.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  The Journal of the National Comprehensive Cancer Network

• Publication date

  2012-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.6004/JNCCN.2008.0042PMID 18597709
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease.

  2010cited by this paper
• Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.

  2010cited by this paper
• Role of Iron Supplementation to Erythropoiesis Stimulating Agents In the Management of Chemotherapy-Induced Anemia In Cancer Patients: A Systematic Review and Meta-Analysis

  2010cited by this paper
• Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

  2010cited by this paper
• Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes

  2010cited by this paper
• Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis

  2009cited by this paper
• Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.

  2009cited by this paper
• Editorial: Intersecting Guidelines: Administering Erythropoiesis‐Stimulating Agents to Chronic Kidney Disease Patients with Cancer

  2009cited by this paper
• Anemia management in oncology and hematology.

  2009cited by this paper
• A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation On the Erythropoietic Response to Darbepoetin Alfa for Patients with Chemotherapy-Associated Anemia: A Study of the Mayo Clinic Cancer Research Consortium (MCCRC).

  2009cited by this paper
• Randomized study of darbepoetin alfa as modifier of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): Final outcome of the DAHANCA 10 trial.

  2009cited by this paper
• Impact of limiting erythropoiesis‐stimulating agent use for chemotherapy‐induced anemia on the United States blood supply margin

  2009cited by this paper
• Autologous stem cell transplants in Jehovah's Witnesses

  2009cited by this paper
• A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

  2009cited by this paper
• A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia.

  2009cited by this paper
• Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications.

  2009cited by this paper
• Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.

  2009cited by this paper
• PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer: A preplanned interim analysis of eff

  2008cited by this paper
• Intravenous Iron Therapy: A Summary of Treatment Options and Review of Guidelines

  2008cited by this paper
• Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer.

  2008cited by this paper
• Epoetin‐associated pure red cell aplasia: past, present, and future considerations

  2008cited by this paper
• Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.

  2008cited by this paper
• Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.

  2008cited by this paper
• Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.

  2008cited by this paper
• Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide.

  2008cited by this paper
• Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes

  2008cited by this paper
• Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.

  2008cited by this paper
• Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia.

  2008cited by this paper
• Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.

  2007cited by this paper
• A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.

  2007cited by this paper
• Guideline : Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer

  2007cited by this paper
• Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

  2007cited by this paper
• Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols.

  2007cited by this paper
• Erythropoietin, the FDA, and oncology.

  2007cited by this paper
• Prognostic Significance of Blood Transfusions in Patients With Esophageal Cancer Treated With Combined Chemoradiotherapy

  2007cited by this paper
• Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

  2007cited by this paper
• Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy

  2007cited by this paper
• Clinical update: intravenous iron for anaemia.

  2007cited by this paper
• 1120 POSTER Evaluation of the association between hemoglobin (Hb) events and safety outcomes in cancer patients (pts) with chemotherapy-induced anemia (CIA): an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials (RCTs) of darbepoetin alfa (DA)

  2007cited by this paper
• Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.

  2006cited by this paper
• The continuing risk of transfusion-transmitted infections.

  2006cited by this paper
• Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer.

  2006cited by this paper
• Update on adverse drug events associated with parenteral iron.

  2006cited by this paper
• Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.

  2006cited by this paper
• Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia*

  2006cited by this paper
• Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.

  2006cited by this paper
• Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.

  2005cited by this paper
• Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial.

  2005cited by this paper
• Anemia of chronic disease.

  2005cited by this paper
• Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

  2005cited by this paper
• The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC

  2004cited by this paper
• Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs

  2004cited by this paper
• Prevalence and outcomes of anemia in surgery: a systematic review of the literature.

  2004cited by this paper
• Evaluation of the US Oncology Network's Recommended Guidelines for Therapeutic Substitution with Darbepoetin alfa 200 μg Every 2 Weeks in Both Naïve Patients and Patients Switched from Epoetin alfa

  2004cited by this paper
• Pure red-cell aplasia and epoetin therapy.

  2004cited by this paper
• Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial.

  2004cited by this paper
• Autologous stem-cell transplantation can be performed safely without the use of blood-product support.

  2004cited by this paper
• Parenteral iron therapy options

  2004cited by this paper
• The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

  2004cited by this paper
• Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.

  2003cited by this paper
• Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double‐blind, placebo‐controlled study

  2003cited by this paper
• Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.

  2002cited by this paper
• Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

  2001cited by this paper
• Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

  2001cited by this paper
• Successful autologous bone marrow transplant without the use of blood product support

  2000cited by this paper
• Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.

  2000cited by this paper
• A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.

  1999cited by this paper
• Chemotherapy-induced anemia in adults: incidence and treatment.

  1999cited by this paper
• Frequency and significance of anemia in non-Hodgkin's lymphoma patients.

  1998cited by this paper
• Haematological toxicity of cranio-spinal irradiation.

  1998cited by this paper
• Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.

  1997cited by this paper
• A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals

  1996cited by this paper
• Equilibration of Hemoglobin Concentration after Transfusion in Medical Inpatients Not Actively Bleeding

  1994cited by this paper
• Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.

  1991cited by this paper
• The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer.

  1988cited by this paper

• Design and Synthesis of Chromene-Triazole Hybrids via Recyclable Magnetic Nanocatalyst: Potent Dual-Acting Anticancer Agents Targeting Apoptotic and Microtubule Dynamics

  2025cites this paper
• Hidden blood loss and its influencing factors after cement augmentation for vertebral metastasis

  2024cites this paper
• The Effect of Self-Care Training on the Severity of Oral Mucositis in Breast Cancer Patients Undergoing Chemotherapy

  2022cites this paper
• The impact of red blood cell transfusion on mortality and treatment efficacy in patients treated with radiation: A systematic review

  2021cites this paper
• Prevalence, etiology and risk factors of anemia in patients with newly diagnosed cancer

  2020cites this paper
• Prevalence of Iron, Vitamin B12 deficiency and inflammatory anaemia in treatment naive individual consecutive cancer patients: A cross sectional study.

  2020cites this paper
• Risk of Anemia in Patients with Newly Identified Chronic Kidney Disease – A Population-Based Cohort Study

  2020cites this paper
• Investigation of Protective Effects of Quercetin on Oxidative Stress Induced by Vinblastine in Bone Marrow of Rats

  2020cites this paper
• Is Darbepoietin Alfa Linked to Mortality During Non-Small Cell Lung Cancer Chemotherapy?

  2020cites this paper
• Benign Hematological Diseases in Cancer Patients

  2019cites this paper
• Impact of Real-Time Clinical Decision Support on Blood Utilization and Outcomes in Hospitalized Patients with Solid Tumor Cancer.

  2019cites this paper
• New thiazole-2(3H)-thiones containing 4-(3,4,5-trimethoxyphenyl) moiety as anticancer agents.

  2019cites this paper
• Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study

  2019cites this paper
• Transfusion Therapy: Is There a Link with Cancer Recurrence?

  2018cites this paper
• Patient Blood Management in Critically Ill

  2018cites this paper
• Роль эритропоэтинов в лечении онкологических больных

  2018cites this paper
• Prise en charge de l’anémie en oncologie thoracique au CHU Amiens-Picardie. Évaluation des pratiques professionnelles entre 2014 et 2016

  2018cites this paper
• Iron deficiency beyond erythropoiesis: should we be concerned?

  2018cites this paper
• A randomized trial of adjunct testosterone for cancer‐related muscle loss in men and women

  2018cites this paper
• Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs

  2018cites this paper
• Cancer; an induced disease of twentieth century! Induction of tolerance, increased entropy and ‘Dark Energy’: loss of biorhythms (Anabolism v. Catabolism)

  2018cites this paper
• Living Through Ovarian Cancer Treatment: Acute and Long-Term Toxicities of Chemotherapy for Advanced-Stage Disease.

  2018cites this paper
• Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation

  2017cites this paper
• A retrospective open-label uncontrolled study of Epoetin zeta on the treatment of chemotherapy-induced anemia in solid tumors

  2017cites this paper
• Indications for and complications of transfusion and the management of gynecologic malignancies.

  2017cites this paper
• Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge.

  2017cites this paper
• Chemotherapeutic Medications and Their Emergent Complications.

  2017cites this paper
• Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study

  2017cites this paper
• Prevalence and prognostic impact of anemia and iron deficiency in patients hospitalized in an internal medicine ward: The PRO‐IRON study

  2017cites this paper
• Evolution and Management of Treatment-Related Toxicity in Anal Cancer.

  2017cites this paper
• Novel herbal medicine LA16001 ameliorates cisplatin-induced anorexia.

  2017cites this paper
• Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer patients with anaemia: A systematic review and network meta‐analysis

  2017cites this paper
• Choosing Wisely: Decreasing the incidence of perioperative blood transfusions in gynecologic oncology.

  2017cites this paper
• Impact of Medicare Reimbursement Policy Change on the Utilization, Risks, and Costs Associated with Erythropoiesis-Stimulating Agents in Cancer Patients with Chemotherapy-Induced Anemia

  2017cites this paper
• Carbon nanotubes: A review of novel strategies for cancer diagnosis and treatment.

  2017cites this paper
• Clinical and Pathologic Predictors of Clinical Outcome of Malignant Pleural Mesothelioma

  2016cites this paper
• Carboplatin-induced hematotoxicity among patients with non-small cell lung cancer: Analysis on clinical adverse events and drug-gene interactions

  2016cites this paper
• Red Blood Cell Transfusion Strategies in Adult and Pediatric Patients with Malignancy.

  2016cites this paper
• Combination with intravenous iron supplementation or doubling erythropoietin dose for patients with chemotherapy-induced anaemia inadequately responsive to initial erythropoietin treatment alone: study protocol for a randomised controlled trial

  2016cites this paper
• Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation

  2016cites this paper
• Screening or Symptoms? How Do We Detect Colorectal Cancer in an Equal Access Health Care System?

  2016cites this paper
• Blood Transfusion Therapy

  2016cites this paper
• Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based Study.

  2016cites this paper
• Nuances in the Management of Older People With Multiple Myeloma

  2016cites this paper
• Methodologic quality assessment of red blood cell transfusion guidelines and the evidence base of more restrictive transfusion thresholds

  2016cites this paper
• Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents.

  2016cites this paper
• Blood Transfusions for Hospitalized Patients with Cancer

  2016cites this paper
• Trends in Anemia Management in Hemodialysis Patients with Cancer

  2015cites this paper
• Characterization of Red Blood Cells with Multiwavelength Transmission Spectroscopy

  2015cites this paper
• Hepcidin in tumor‐related iron deficiency anemia and tumor‐related anemia of chronic disease: pathogenic mechanisms and diagnosis

  2015cites this paper
• Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study

  2015cites this paper
• Factors Associated with Fatigue in Korean Gastric Cancer Survivors

  2015cites this paper
• hematology Board review manual Cancer-related anemia

  2015cites this paper
• Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations

  2015cites this paper
• Management of Various Patients in Day Care Transfusion Center at Transfusion Medicine Department of Dhaka Medical College Hospital, Dhaka - Annual Audit of 2013

  2015cites this paper
• Can administrative data be used to measure chemotherapy side effects?

  2015cites this paper
• Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation

  2015influential citation
• Transfusions of blood products and cancer outcomes.

  2015cites this paper
• Transfusion Medicine in Sub-Saharan Africa: Conference Summary.

  2015cites this paper
• The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study

  2015influential citation
• Iron deficiency in gastrointestinal oncology

  2015cites this paper
• Prevention and Management of Hospital-Acquired Anemia

  2014cites this paper
• Supportive Therapie und Schmerzbehandlung

  2014cites this paper
• Impact of preoperative anemia on relapse and survival in breast cancer patients

  2014cites this paper
• Entwicklung und Umsetzung eines integrierten Behandlungspfads in den POLIKUM-Gesundheitszentren am Beispiel der Anämie

  2014cites this paper
• Iron deficiency anemia--bridging the knowledge and practice gap.

  2014cites this paper
• Romiplostim for management of chemotherapy-induced thrombocytopenia

  2014cites this paper
• Erythropoiesis-stimulating agents in the management of cancer patients with anemia: a meta-analysis.

  2014cites this paper
• INADEQUATE IRON THERAPY CANNOT PREVENT ANEMIA FOLLOWING CHEMOTHERAPY IN BREAST CANCER PATIENTS

  2014cites this paper
• Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy

  2014cites this paper
• Chemotherapeutic medications and their emergent complications.

  2014cites this paper
• Current quandaries in cancer-associated anemia.

  2014cites this paper
• SMAC-armed vaccinia virus induces both apoptosis and necroptosis and synergizes the efficiency of vinblastine in HCC

  2014cites this paper
• The Cancer Burden and Patterns of Erythropoiesis-stimulating Agent Use Among End-stage Renal Disease Patients on Hemodialysis

  2014cites this paper
• DIFFERENCES OF TUMOR MASSES AND HEMOGLOBIN LEVELS IN CERVICAL CANCER SQUAMOUS CELL TYPE PATIENTS TREATED WITH COMBINATION OF PACLITAXEL AND CARBOPLATIN CHEMOTHERAPY

  2014cites this paper
• Anaemia in Quick Diagnostic Unit

  2014cites this paper
• Impact of anemia on erythropoietin and erythropoietin receptor expression: correlation with the proliferation of breast cancer cells

  2013cites this paper
• Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?

  2013cites this paper
• Concepts of blood transfusion in adults.

  2013cites this paper
• Fatigue in Other Medical Disorders

  2013cites this paper
• PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

  2013cites this paper
• Administration of intravenous iron complexes on implantable central venous access port in cancer patients in France: the FERPAC survey

  2013cites this paper
• The impact of chemotherapy in cancer patients: reflection on traditional Chinese symptom complex, cancer-related fatigue, and quality of life.

  2013cites this paper
• Budget impact analysis on erythropoiesis–stimulating agents use for the management of chemotherapy-induced anaemia in Greece

  2013cites this paper
• Erythropoietin or darbepoetin for patients with cancer.

  2012cites this paper
• Becoming smarter about parenteral iron use in the oncology clinic

  2012cites this paper
• Intravenous iron in chemotherapy and cancer-related anemia

  2012cites this paper
• Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002–2008

  2012cites this paper
• Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells

  2012cites this paper
• Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009.

  2011cites this paper
• Clinical practice guidelines for the use of erythroid-stimulating agents: ASCO, EORTC, NCCN.

  2011cites this paper
• The prognostic impact of duration of anemia during chemotherapy in advanced epithelial ovarian cancer.

  2011cites this paper
• RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy

  2011cites this paper
• Original article RETRA: evaluating the transfusion rate with darbepoetin alfa 500mg every 3 weeks in anaemic cancer patients receiving chemotherapy

  2011cites this paper
• Anemia management in chronic kidney disease: Intravenous iron steps forward

  2010cites this paper
• Everolimus in relapsed Hodgkin's lymphoma: Something exciting or a case of caveat mTOR?

  2010cites this paper
• Disorders of iron metabolism. Part II: iron deficiency and iron overload

  2010cites this paper
• Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study.

  2010cites this paper
• Anemia, fatigue and aging.

  2010cites this paper
• Cancer-Related Fatigue

  2010cites this paper